Patents by Inventor Paul William THOMPSON

Paul William THOMPSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS
    Publication number: 20230312580
    Abstract: The present invention relates to hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitriles with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis:.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 5, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON, Martin Lee STOCKLEY
  • N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20230303547
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquity lating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (formulae (I)(i) and (I)(ii)).
    Type: Application
    Filed: June 3, 2021
    Publication date: September 28, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION
    Publication number: 20230219939
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: Formula (I), Formula (II).
    Type: Application
    Filed: May 27, 2021
    Publication date: July 13, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20230119013
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis.
    Type: Application
    Filed: April 7, 2021
    Publication date: April 20, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20220315572
    Abstract: The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (I).
    Type: Application
    Filed: September 3, 2020
    Publication date: October 6, 2022
    Inventors: Paul William THOMPSON, Christopher Andrew LUCKHURST, Mark Ian KEMP
  • CYANOPYRROLIDINES AS USP30 INHIBITORS AND FIBROSIS TREATMENT
    Publication number: 20210002262
    Abstract: The present invention relates to novel treatments of fibrotic diseases, including, inter alia, fibrosis of the lung, liver and kidney, and to substituted-cyanopyrrolidines of formula (I) having activity as inhibitors of ubiquitin specific peptidase 30 (USP30), and compositions containing said inhibitors, for use in said treatments (I).
    Type: Application
    Filed: March 5, 2019
    Publication date: January 7, 2021
    Inventors: Paul William THOMPSON, Anne PHELAN, Martin Lee STOCKLEY, Mark Ian KEMP